PXSLY - Pharmaxis Ltd

Other OTC - Other OTC Delayed Price. Currency in USD
3.1200
0.0000 (0.00%)
At close: 9:30AM EDT
Stock chart is not supported by your current browser
Previous Close3.1200
Open3.1200
BidN/A x N/A
AskN/A x N/A
Day's Range3.1200 - 3.1200
52 Week Range3.1200 - 3.9600
Volume150
Avg. Volume9
Market Cap72.729M
Beta (3Y Monthly)-0.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire6 months ago

    Arix Bioscience plc: Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for Second LOXL2 Inhibitor Compound

    Arix Bioscience plc ("Arix") (ARIX.L), a global healthcare and life science company supporting medical innovation, is pleased to note that Pharmaxis Ltd (PXS.AX), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF). Arix led the A$24 million (£13.4 million) financing for Pharmaxis in August, acquiring an 11.1% equity stake.

  • PR Newswire7 months ago

    Arix Bioscience plc : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound

    Arix Bioscience plc ("Arix") (ARIX.L), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Pharmaxis Ltd (PXS.AX), an Australian pharmaceutical research company focused on inflammation and fibrosis, today announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fibrosis (IPF). The announcement can be accessed on Pharmaxis' website at http://www.pharmaxis.com.au/investor-centre/news/ and full text of the announcement from Pharmaxis is contained below.

  • With An ROE Of 53.94%, Has Pharmaxis Ltd’s (ASX:PXS) Management Done Well?
    Simply Wall St.11 months ago

    With An ROE Of 53.94%, Has Pharmaxis Ltd’s (ASX:PXS) Management Done Well?

    This analysis is intended to introduce important early concepts to people who are starting to invest and want to better understand how you can grow your money by investing inRead More...